Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 15:13:4229-4237.
doi: 10.2147/OTT.S243221. eCollection 2020.

MicroRNA-374b-5p Functions as a Tumor Suppressor in Non-Small Cell Lung Cancer by Targeting FOXP1 and Predicts Prognosis of Cancer Patients

Affiliations

MicroRNA-374b-5p Functions as a Tumor Suppressor in Non-Small Cell Lung Cancer by Targeting FOXP1 and Predicts Prognosis of Cancer Patients

Jianzhao Li et al. Onco Targets Ther. .

Abstract

Background: Lung cancer remains the most frequent malignancy worldwide with increasing morbidity and mortality. This study aimed to assess the expression of microRNA-374b-5p (miR-374b-5p) in tissues and cell lines of non-small cell lung cancer (NSCLC) and to evaluate the prognostic value of miR-374b-5p as well as its biological function in tumor progression.

Materials and methods: Expression of miR-374b-5p in NSCLC patients and cells was estimated using quantitative real-time PCR. The prognostic value of miR-374b-5p was evaluated using Kaplan-Meier method and Cox regression analysis. Gain-of-function and loss-of-function cell experiments were performed to examine the effects of miR-374b-5p on NSCLC cell proliferation, migration and invasion. A luciferase activity assay was used to confirm the target gene of miR-374b-5p.

Results: miR-374b-5p expression levels were decreased in tumorous tissues and cell lines compared with the normal tissues or cells (P < 0.05). The expression of miR-374b-5p was associated with the patients' tumor size, lymph node metastasis and TNM stage (all P < 0.05). Patients with low miR-374b-5p expression have a shorter survival time (log-rank P = 0.001), and the downregulated expression of miR-374b-5p was determined to be an independent prognostic indicator of NSCLC. In NSCLC cells, the overexpression of miR-374b-5p could inhibit NSCLC cell proliferation, migration and invasion and could directly target FOXP1.

Conclusion: This study found that the decreased miR-374b-5p predicts poor prognosis of NSCLC, and the upregulation of miR-374b-5p can inhibit NSCLC cell proliferation, migration and invasion. The data obtained from this study provide a novel candidate prognostic biomarker and a potential therapeutic target for NSCLC.

Keywords: invasion; microRNA-374b-5p; migration; non-small cell lung cancer; prognosis; proliferation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Expression of miR-374b-5p in NSCLC. (A) Expression of miR-374b-5p in the tissue samples collected from NSCLC patients. (B) Different expression levels of miR-374b-5p in four NSCLC cell lines. ***P < 0.001.
Figure 2
Figure 2
Kaplan-Meier survival curves for NSCLC patients based on different miR-374b-5p expressions. Log-rank P =0.001.
Figure 3
Figure 3
Effects of miR-374b-5p on cell proliferation, migration and invasion of A549 and H460 cells. (A) Cell transfection efficiency examination results. (B) Inhibiting effect of miR-374b-5p on NSCLC cell proliferation. (C and D) miR-374b-5p suppressed NSCLC cell migration (C) and invasion (D). *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 4
Figure 4
The prediction and confirmation of a target gene FOXP1 of miR-374b-5p. (A) The complementary sequence of miR-374b-5p in the 3ʹ-UTR of FOXP1. (B) Luciferase activity assay to verify the interaction between miR-374b-5p and FOXP1 (*P < 0.05). (C) Relative mRNA expression of FOXP1 in tissues collected from NSCLC patients (***P < 0.001). (D) Correlation between miR-374b-5p expression and FOXP1 mRNA expression in NSCLC patients.

Similar articles

Cited by

References

    1. Hoffman RM, Sanchez R. Lung cancer screening. Med Clin North Am. 2017;101(4):769–785. doi:10.1016/j.mcna.2017.03.008 - DOI - PMC - PubMed
    1. Peng W, Wang J, Shan B, et al. Diagnostic and prognostic potential of circulating long non-coding RNAs in non-small cell lung cancer. Cell Physiol Biochem. 2018;49(2):816–827. doi:10.1159/000493043 - DOI - PubMed
    1. Nascimento AV, Bousbaa H, Ferreira D, Sarmento B. Non-small cell lung carcinoma: an overview on targeted therapy. Curr Drug Targets. 2015;16(13):1448–1463. doi:10.2174/1389450115666140528151649 - DOI - PubMed
    1. Wang X, Zhang Y, Zhi X. Correlation between microRNA expression, clinicopathological characteristics, and prognosis in patients with non-small cell lung cancer: a retrospective study. Thorac Cancer. 2017;8(5):511–516. doi:10.1111/1759-7714.12480 - DOI - PMC - PubMed
    1. Bhaskaran M, Mohan M. MicroRNAs: history, biogenesis, and their evolving role in animal development and disease. Vet Pathol. 2014;51(4):759–774. doi:10.1177/0300985813502820 - DOI - PMC - PubMed